by Eric Christianson | May 12, 2024 | Clinical Pharmacy News and New Drug Updates, Gastrointestinal Medication and Disease State Clinical Pearls
On November 1, 2023, the U.S. Food and Drug Administration (FDA) approved VOQUEZNA® (vonoprazan) as a new treatment for the healing and maintenance of erosive esophagitis and the relief of heartburn associated with erosive esophagitis in adults. This FDA approval...
by Eric Christianson | Apr 17, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Trazodone belongs to a class of drugs called serotonin antagonist and reuptake inhibitors (SARIs). Although trazodone is only FDA-approved for the treatment of major depressive disorder (MDD), it is most often used off-label to manage insomnia. What’s interesting...
by Eric Christianson | Jan 14, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
Fenofibrate is a lipid-lowering medication indicated as monotherapy to treat primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. While this medication has been around for many years, its formulation has continued to evolve. The different fenofibrate...
by Eric Christianson | Dec 13, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Alcohol use disorder can be managed with medications. American Psychiatric Association Guidelines recommend acamprosate or naltrexone as a first-line agent for moderate to severe management of alcohol use disorder. In this article, I will compare acamprosate versus...
by Eric Christianson | Nov 1, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
Calcium channel blockers (CCBs) are split into two categories, dihydropyridines (DHP), such as amlodipine and nicardipine, and non-dihydropyridines (non-DHP), such as verapamil and diltiazem. While these two drug classes are both CCBs, there are some key similarities...
